-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 2, Tasly issued an announcement stating that its wholly-owned subsidiary Tasly (North America) Pharmaceutical Co.
, Ltd.
(referred to as "North American Pharmaceuticals") received the US FDA's approval of the new chemical drug JS1-1-01 tablets for moderate to severe use.
Notification of clinical trials for the treatment of depression (IND number: 153206)
.
The therapeutic biological product "Human Growth Hormone Injection" independently developed by North American Pharmaceuticals was approved by the National Medical Products Administration in June 2019 (Specifications: 4IU/1.
33mg/1ml/bottle, 10IU/3.
33mg/1ml/ Support)
.
A total of 6 indications have been approved: 1.
This product is based on the original two specifications on the market, this time it has been approved by the National Medical Products Administration to add two new specifications: 6IU/2mg/0.
6ml/bottle and 8IU/2.
66mg/0.
8ml/bottle
.
So far, a total of 4 specifications of human growth hormone injection from North American Pharmaceuticals have been approved for marketing